Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report

Horie,Tatsuo; Kijima,Tsunetaka; Yamaguchi,Minekazu; Honda,Satoshi; Horie,Miyako; Ishitobi,Kazunari; Yamagata,Shingo; Sakano,Shigeru; Kurokohchi,Kazutaka

doi:10.3892/mco.2021.2223

Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report

Authors:
- Tatsuo Horie
- Tsunetaka Kijima
- Minekazu Yamaguchi
- Satoshi Honda
- Miyako Horie
- Kazunari Ishitobi
- Shingo Yamagata
- Shigeru Sakano
- Kazutaka Kurokohchi
View Affiliations

Affiliations: Department of Pharmacy, Oda Municipal Hospital, Oda, Shimane 694‑0063, Japan, Department of General Medicine, Shimane University Faculty of Medicine, Oda General Medicine Education Center, Oda, Shimane 694‑0063, Japan, Department of Surgery, Oda Municipal Hospital, Oda, Shimane 694‑0063, Japan
Published online on: January 25, 2021 https://doi.org/10.3892/mco.2021.2223
Article Number: 61
Copyright: © Horie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study reports the case of an 80‑year‑old woman who experienced severe hypoglycaemia after abemaciclib administration, with a recovery time of ~46 h. Abemaciclib is a cyclin‑dependent kinase 4 and 6 (CDK4/6) inhibitor that is used to treat metastatic breast cancer. A side effect of abemaciclib administration is an increase in creatinine levels. The half‑life (t_1/2) of 150 mg abemaciclib in patients with breast cancer was reported to be 17.5 h (nearly lower limit), and the time to reach C_max was ~5 h (T_max, 4‑6 h). Therefore, the total time to reach half the maximum blood concentration after abemaciclib administration is ~24 h (T_max + t1/2=5+17.5=22.5 h). As abemaciclib is administered twice daily, a considerable amount (C_max = 123 ng/ml) may persist in the blood following the initial dose. Upon repeated administration, the blood abemaciclib concentration in patients with metastatic liver tumours might increase, although their liver function remains normal. The patient described in the current study had a creatinine level of 1.05 mg/dl at the start of abemaciclib administration. At the time of emergency hospitalisation (on day 5 of abemaciclib administration), the creatinine level was 1.40 mg/dl; however, dehydration was not observed. The patient had been administered the same dose of glimepiride for >1 year and had not experienced hypoglycaemia previously. It can be speculated that the increase in blood creatinine level had some effect on glimepiride metabolism. It is thought that administered abemaciclib enhances metabolic delay in the blood in the same way as in patients with impaired liver function, and as a result, the creatinine level increases in patients with liver metastases. This causes a decrease in renal function, which in turn results in an increase in blood concentration of glimepiride, consequently leading to severe hypoglycaemia. Therefore, clinicians must be careful when using abemaciclib in patients with liver metastases, diabetes and poor renal function.

View Figures

View References

1	Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo B, Evans D, Feachem RGA, Frenk J, et al: Global health 2035: A world converging within a generation. Lancet. 382:1898–1955. 2013.PubMed/NCBI View Article : Google Scholar
2	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
3	Raftery AE, Li N, Ševčíková H, Gerland P and Heilig GK: Bayesian probabilistic population projections for all countries. Proc Natl Acad Sci USA. 109:13915–13921. 2012.PubMed/NCBI View Article : Google Scholar
4	Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 157(107843)2019.PubMed/NCBI View Article : Google Scholar
5	Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, et al: MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR⁺/HER2^- metastatic breast cancer. Clin Cancer Res. 23:5218–5224. 2017.PubMed/NCBI View Article : Google Scholar
6	Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: MONARCH 2: Abemaciclib, in combination with Fulvestrant in women with HR⁺/HER2^- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 35:2875–2884. 2017.PubMed/NCBI View Article : Google Scholar
7	Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, et al: MONARCH 3: Abemaciclib, as initial therapy for advanced breast cancer. J Clin Oncol. 35:3638–3646. 2017.PubMed/NCBI View Article : Google Scholar
8	Draeger E: Clinical profile of glimepiride. Diabetes Res Clin Pract. 28:139–146. 1995.PubMed/NCBI View Article : Google Scholar
9	Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E and Rosskamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res. 28:419–425. 1996.PubMed/NCBI View Article : Google Scholar
10	Badian M, Korn A, Lehr KH, Malerczyk V and Waldhäusl W: Absolute bioavailability of Glimepiride (Amaryl) after oral administration. Drug Metabol Drug Interact. 11:331–339. 1994.PubMed/NCBI View Article : Google Scholar
11	Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ and Kivistö KT: Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 72:326–332. 2002.PubMed/NCBI View Article : Google Scholar
12	Otagiri M: Study on binding of drug to serum protein. Yakugaku Zasshi. 129:413–425. 2009.PubMed/NCBI View Article : Google Scholar : (In Japanese).
13	Meyer MC and Guttman DE: The binding of drugs by plasma proteins. J Pharm Sci. 57:895–918. 1968.PubMed/NCBI View Article : Google Scholar
14	Jusko WJ and Gretch M: Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev. 5:43–140. 1976.PubMed/NCBI View Article : Google Scholar
15	Vallner JJ: Binding of drugs by albumin and plasma protein. J Pharm Sci. 66:447–465. 1977.PubMed/NCBI View Article : Google Scholar
16	Langtry HD and Balfour JA: Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 55:563–584. 1998.PubMed/NCBI View Article : Google Scholar
17	Wang D, Sun Y, Li W, Ye F, Zhang Y, Guo Y, Zhang DY and Suo J: Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells. Int J Mol Med. 41:2473–2484. 2018.PubMed/NCBI View Article : Google Scholar
18	Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, et al: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 48:2388–2406. 2005.PubMed/NCBI View Article : Google Scholar
19	Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG and Wu K: Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 10(97)2017.PubMed/NCBI View Article : Google Scholar
20	Li B, He H, Tao BB, Zhao ZY, Hu GH, Luo C, Chen JX, Ding XH, Sheng P, Dong Y, et al: Knockdown of CDK6 enhances glioma sensitivity to chemotherapy. Oncol Rep. 28:909–914. 2012.PubMed/NCBI View Article : Google Scholar
21	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009.PubMed/NCBI View Article : Google Scholar
22	Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, et al: Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol. 78:281–288. 2016.PubMed/NCBI View Article : Google Scholar
23	Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6:740–753. 2016.PubMed/NCBI View Article : Google Scholar
24	Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK and Cronier DM: A population pharmacokinetic and pharmacodynamic analysis of abemaciclib, in a phase I clinical trial in cancer patients. Clin Pharmacokinet. 57:335–344. 2018.PubMed/NCBI View Article : Google Scholar
25	Rosenkranz B: Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 28:434–439. 1996.PubMed/NCBI View Article : Google Scholar
26	Kacevska M, Robertson GR, Clarke SJ and Liddle C: Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: Impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 4:137–149. 2008.PubMed/NCBI View Article : Google Scholar
27	Fahy BN, Guo T and Ghose R: Impact of hepatic malignancy on CYP3A4 gene expression. J Surg Res. 178:768–772. 2012.PubMed/NCBI View Article : Google Scholar
28	Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C and Malerczyk V: Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 39:1617–1624. 1996.PubMed/NCBI View Article : Google Scholar
29	Hou L, Zhao T, Liu Y and Zhang Y: Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. Exp Ther Med. 9:1528–1536. 2015.PubMed/NCBI View Article : Google Scholar
30	DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 131:281–303. 1999.PubMed/NCBI View Article : Google Scholar
31	Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 287:360–372. 2002.PubMed/NCBI View Article : Google Scholar
32	Levey AS, Perrone RD and Madias NE: Serum creatinine and renal function. Annu Rev Med. 39:465–490. 1988.PubMed/NCBI View Article : Google Scholar
33	Pun KK, Young RTT, Wang C, Tam CF and Ho PWM: The use of glucagon challenge tests in the diagnostic evaluation of hypoglycemia due to hepatoma and insulinoma. J Clin Endocrinol Metab. 67:546–550. 1988.PubMed/NCBI View Article : Google Scholar